PMID- 32670296
OWN - NLM
STAT- MEDLINE
DCOM- 20210405
LR  - 20210405
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - The Role of HLA-G in Human Papillomavirus Infections and Cervical Carcinogenesis.
PG  - 1349
LID - 10.3389/fimmu.2020.01349 [doi]
LID - 1349
AB  - Human leukocyte antigen (HLA)-G, a non-classical HLA-class I molecule, has a low 
      polymorphism frequency, restricted tissue distribution and immunoinhibitory 
      property. HLA-G expression in tumor cells and cells chronically infected with 
      virus may enable them to escape from host immune surveillance. It is well-known 
      that the HLA-G molecule is a novel biomarker and potential therapeutic target 
      that is relevant in various types of cancers, but its role in cervical cancer has 
      not been fully explored. In this review, we aim to summarize and discuss the 
      immunologic role of the HLA-G molecule in the context of HPV infections and the 
      process of cervical cancer carcinogenesis. A better understanding of the 
      potential impact of HLA-G on the clinical course of persistent HPV infections, 
      cervical epithelial cell transformation, tumor growth, recurrence and metastasis 
      is needed to identify a novel diagnostic/prognostic biomarker for cervical 
      cancer, which is critical for cervical cancer risk screening. In addition, it is 
      also necessary to identify HLA-G-driven immune mechanisms involved in the 
      interactions between host and virus to explore novel immunotherapy strategies 
      that target HLA-G/immunoglobulin-like transcript (ILT) immune checkpoints.
CI  - Copyright (c) 2020 Xu, Yan and Lin.
FAU - Xu, Hui-Hui
AU  - Xu HH
AD  - Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical 
      University, Linhai, China.
FAU - Yan, Wei-Hua
AU  - Yan WH
AD  - Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical 
      University, Linhai, China.
FAU - Lin, Aifen
AU  - Lin A
AD  - Biological Resource Center, Taizhou Hospital of Zhejiang Province, Wenzhou 
      Medical University, Linhai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200625
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (HLA-G Antigens)
SB  - IM
MH  - Carcinogenesis/*immunology
MH  - Female
MH  - HLA-G Antigens/*immunology
MH  - Humans
MH  - Papillomavirus Infections/*complications/*immunology
MH  - Uterine Cervical Neoplasms/*immunology/pathology/virology
PMC - PMC7330167
OTO - NOTNLM
OT  - carcinogenesis
OT  - cervical cancer
OT  - human leukocyte antigen G
OT  - human papillomavirus
OT  - immunotherapy
OT  - viral infection
EDAT- 2020/07/17 06:00
MHDA- 2021/04/07 06:00
PMCR- 2020/01/01
CRDT- 2020/07/17 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/05/27 00:00 [accepted]
PHST- 2020/07/17 06:00 [entrez]
PHST- 2020/07/17 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.01349 [doi]
PST - epublish
SO  - Front Immunol. 2020 Jun 25;11:1349. doi: 10.3389/fimmu.2020.01349. eCollection 
      2020.